Informations sur le produit
- (16Alpha,17Beta)-3-(Cyclopentyloxy)-17-Ethynylestra-1,3,5(10)-Triene-16,17-Diol
- (16a,17b)-3-(Cyclopentyloxy)-17-ethynylestra-1,3,5(10)-triene-16,17-diol
- (16alpha,17beta)-3-(Cyclopentyloxy)-17-ethynylestra-1(10),2,4-triene-16,17-diol
- (16α,17α)-3-(Cyclopentyloxy)-19-norpregna-1,3,5(10)-trien-20-yne-16,17-diol
- 17a-Ethynylestra-1,3,5(10)-triene-3,16a,17b-triol 3-Cyclopentyl Ether
- 17alpha-Ethynylestra-1,3,5(10)-triene-3,16alpha,17beta-triol 3-cyclopentyl ether
- 17α-Ethynylestriol 3-cyclopentyl ether
- 19-Norpregna-1,3,5(10)-trien-20-yne-16,17-diol, 3-(cyclopentyloxy)-, (16α,17α)-
- 3-Cyclopentyloxy-19-nor-17α-pregna-1,3,5(10)-trien-20-yne-16α,17β-diol
- 39791-20-3
- Voir d'autres synonymes
- EE<sub>3</sub>CPE
- Nylestriol
- WeiNiAn
Nilestriol is a synthetic estrogen that is used in the treatment of postmenopausal osteoporosis and other symptoms associated with menopause. It has been shown to inhibit the growth of cancer tissues by binding to hydroxyl groups. Nilestriol also binds to transcription-polymerase chain, which prevents RNA synthesis. This may lead to a decrease in levels of growth factor-β1, which is known to stimulate bone resorption. The long-term efficacy of nilestriol has been demonstrated in intrauterine studies with rats and monkeys. In these studies nilestriol was found to be non-toxic and effective at preventing uterine hyperplasia or endometrial cancer.